abs

학술발표회초록보기

초록문의 abstract@kcsnet.or.kr

결제문의 member@kcsnet.or.kr

현재 가능한 작업은 아래와 같습니다.
  • 05월 20일 18시 이후 : 초록수정 불가능, 일정확인 및 검색만 가능

제125회 대한화학회 학술발표회 및 총회 NRDO, New Business Model for Innovative Drug Development and Its Case Story

등록일
2020년 5월 27일 09시 22분 25초
접수번호
2549
발표코드
ORGN3-2 이곳을 클릭하시면 발표코드에 대한 설명을 보실 수 있습니다.
발표시간
화 15시 : 20분
발표형식
심포지엄
발표분야
Organic Chemistry - Current Trends in Medicinal Chemistry & Chemical Biology
저자 및
공동저자
James Jungkue Lee
Business Development, Commercialization, Drug Development, Bridge Biotherapeutics, Inc., Korea
Commercialization of innovative drugs is a long journey of more than 10 years from basic discovery to marketing approval from health authorities. And it requires multi-disciplinary team covering basic research, medicinal chemistry, process chemistry, clinical science, and regulatory capabilities. In the meantime, drug discovery and drug development require differing skillsets, expertise and culture.

NRDO, No Research Development Only, is a business model for drug development, and focuses only preclinical and clinical development while drug candidates are discovered somewhere else, typically by academic researchers or researchers from research institutes and brought in to NRDO companies.

Licensing to NDRO, by originators allows basic researchers to focus on expertise in their comort zone while NRDO can focus on area of its own strengths, clinical development.

Bridge Biotherapeutics, Inc., is a clinical stage, NRDO type biotech company founded 2015. Since its inception, it brought in three drug candidates and has been developing them to clinical stage. BBT-877, novel autotaxin inhibitor, was licensed from another biotech company, LegoChem Biosciences, back in 2017 and was put in clinic 2019. With its PK data and PD biomarker data from Phase 1 in healthy volunteers, it was licensed out to Boehringer Ingelheim at 1.1 billion Euro price tag.

In this presentation, NRDO business model is given to audience as one of commercialization strategy which basic research can consider for their innovations, and BBT-877 case will be given as successful case.

상단으로